SCHEMBL3093396

SCHEMBL3093396

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cc(Cl)cc(Cl)c2N)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.41
MAPT P10636 4/20 0.40
F2 P00734 3/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PARG Q86W56 1/20 0.40
GPR27 Q9NS67 4/20 0.39
LMNA P02545 2/20 0.38
TP53 P04637 2/20 0.38
CTSD P07339 1/20 0.38
AVPR2 P30518 1/20 0.37
F10 P00742 1/20 0.37
BCL2 P10415 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092326 0.91 F2 (0.42) LARS1MAPTF2KMT2AGPR27
SCHEMBL3096934 0.90 LARS1 (0.42) LARS1MAPTF2GAAMEN1
SCHEMBL3092294 0.90 LARS1 (0.42) LARS1MAPTF2GAAMEN1
SCHEMBL3086202 0.89 SMO (0.46) LARS1MAPTF2GAAMEN1
SCHEMBL3093418 0.88 FLT1 (0.43) LARS1MAPTF2GAAMEN1
SCHEMBL3097119 0.88 FLT1 (0.43) LARS1MAPTF2GAAMEN1
SCHEMBL3096503 0.87 LARS1 (0.45) LARS1MAPTF2MEN1KMT2A
SCHEMBL3096098 0.87 LARS1 (0.45) LARS1MAPTF2MEN1KMT2A
SCHEMBL3090974 0.86 MEN1 (0.50) LARS1MAPTF2GAAMEN1
SCHEMBL3091891 0.86 F2 (0.43) LARS1MAPTF2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885MAPT 2813/4885F2 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.